Provided by Tiger Trade Technology Pte. Ltd.

Beam Therapeutics, Inc.

24.77
-0.4600-1.82%
Post-market: 25.000.2263+0.91%19:02 EDT
Volume:2.34M
Turnover:58.16M
Market Cap:2.56B
PE:-29.57
High:25.37
Open:24.64
Low:24.45
Close:25.23
52wk High:38.26
52wk Low:20.23
Shares:103.29M
Float Shares:91.60M
Volume Ratio:1.26
T/O Rate:2.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8376
EPS(LYR):-0.8100
ROE:-8.18%
ROA:-17.01%
PB:2.40
PE(LYR):-30.58

Loading ...

Clear Street Remains a Buy on Beam Therapeutics (BEAM)

TIPRANKS
·
Aug 05

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 05

Beam Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 04

Earnings Flash (BEAM) Beam Therapeutics Posts Q2 Loss $1.18 a Share, vs. FactSet Est of $1.11 Loss

MT Newswires Live
·
Aug 04

Beam Therapeutics Q2 Operating Expenses USD 127.043 Million

THOMSON REUTERS
·
Aug 04

Beam Therapeutics Q2 License and Collaboration Revenue USD 490 Thousand

THOMSON REUTERS
·
Aug 04

Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of Beam-302 Trial in Alpha-1 Antitrypsin Deficiency (Aatd)

THOMSON REUTERS
·
Aug 04

Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)

GlobeNewswire
·
Aug 04

Scribe's Genetic Editing Aims to Prevent Heart Attacks

Dow Jones
·
Jul 30

Beam Therapeutics Announces Press Release Availability

Reuters
·
Jul 23

Beam Therapeutics (BEAM) Following Ark Invest Interest And Clinical Milestones Looks Undervalued

Simply Wall St.
·
Jul 23

TD Cowen says arbitration decision removes overhang for Prime Medicine’s PM647

TIPRANKS
·
Jul 09

Resolution in favor of Prime has limited impact to Beam, says BofA

TIPRANKS
·
Jul 08

Prime Medicine Wins Arbitration with Beam over AATD Therapy PM647

Reuters
·
Jul 08

Ambarella, Beam, United Micro, Hyperscale Data, Atai Beckley Shocking Insider Moves

TIPRANKS
·
Jul 04

Beam Therapeutics CEO John M. Evans Disposes of 49,000 Common Shares Worth $1.72 Million

Reuters
·
Jul 02

FMR Reports $10.04 Million Beam Therapeutics Common Share Sale

Reuters
·
Jun 30

Beam Therapeutics (BEAM) Could Be 78% Undervalued As FDA Clears BEAM 304

Simply Wall St.
·
Jun 25

Why Beam Therapeutics (BEAM) Is Up 16.1% After FDA Clears Platform-Based PKU Gene-Editing Trial

Simply Wall St.
·
Jun 20

Beam Therapeutics says FDA clears IND for PKU candidate BEAM-304

Reuters
·
Jun 18